News

Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to

With the S&P 500 index recently hitting a new all-time high, we can officially declare that we are in a bull market. While that's exciting news, it doesn't change the blueprint of success for

What's the appeal of investing in relatively small and little-known corporations? Though these businesses come with heightened risks, getting in on the ground floor can potentially be lucrative over

Novavax (NASDAQ: NVAX) shares have offered investors a roller coaster ride over the past few years. They soared more than 2,700% in early pandemic days as investors bet on the company's

While the wireless business is the largest contributor to AT&T's (NYSE: T) revenue by far, the fiber internet business is proving to be a potent growth opportunity. Capturing that growth comes at a

Pfizer (NYSE: PFE) has reached a major transition point. The big pharma company took center stage earlier in the COVID-19 pandemic when it became the first to launch a coronavirus vaccine. That

A few years ago, biotech company Novavax (NASDAQ: NVAX) looked like a promising stock. It emerged as a leader in the development of a COVID-19 vaccine, which sent its share price through the roof.

I'll readily admit that I've picked some supposed growth stocks in the past that didn't deliver much growth. The good news, though, is that my winners have far outpaced my losers over the long run.

Cancer bites, but Amgen (NASDAQ: AMGN) is going to keep biting back. In fact, it's currently developing a handful of oncology medicines that it describes as bispecific T-cell engager therapies, or

Companies focusing on developing gene editing therapies have made significant progress over the past year. However, that has done little to keep Intellia Therapeutics (NASDAQ: NTLA) afloat. The

There was a lot of promise around Novavax (NASDAQ: NVAX) and its COVID vaccine a few years ago. But with the company being late to the finish line and now generating limited revenue from the

Time in the market beats timing the market, hands-down. But how long should you own a stock?

Famed investor Warren Buffett perhaps said it best: "When we own portions of outstanding businesses with

Shares of telecom giant AT&T (NYSE: T) headed lower last Wednesday following a fourth-quarter report that was a bit less positive than investors may have been expecting. Overall, the company's

It's not often that a stock hits a 30-year low, but AT&T (NYSE: T) did just that last summer in the wake of revelations that "toxic" lead-clad cables left behind underground and underwater by the

AT&T's (NYSE: T) shares fell after earnings, but there were some positive signs for the telecom company. Travis Hoium covers the report, and where there were strengths and weaknesses, in this video.

One day after reporting fourth-quarter figures that disappointed many investors, AT&T (NYSE: T) stock bounced back nicely on Thursday. Buoyed by several analyst price target increases, the sturdy

Those who put money in Vertex Pharmaceuticals (NASDAQ: VRTX) 10 years ago are sitting pretty right now. The company has easily outpaced the market over this period.

However, a lot has changed for

Sarepta Therapeutics (NASDAQ: SRPT) and Vertex Pharmaceuticals (NASDAQ: VRTX) have a lot in common: Both operate in the tricky biotech industry, and both seek to develop treatments primarily for

Building a balanced portfolio requires careful planning and execution. You need to think about your long-term objectives for growth and income, as well as tax implications, when you need to adjust

As you build your portfolio through the years, you may find that you gravitate toward stocks across an assortment of sectors, with a range of risk profiles, growth stories, and businesses

AT&T (NYSE: T) stock lost ground in Wednesday's daily trading. The telecom company's share price closed out the session down 3%, according to data from S&P Global Market Intelligence.

AT&T published

Image source: The Motley Fool.

AT&T (NYSE: T)Q4 2023 Earnings CallJan 24, 2024, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

Abbott Laboratories (NYSE: ABT)Q4 2023 Earnings CallJan 24, 2024, 9:00 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of AT&T (NYSE: T) were falling today after strong phone subscriber additions were overshadowed by weak guidance for the new year.

After gaining yesterday in sympathy with a

It finally happened. About 10 years after being created, gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP) earned approval for its first therapy late last year. The treatment in question is